Sumitomo Mitsui Trust Holdings Inc. trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN – Get Rating) by 0.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 462,141 shares of the life sciences company’s stock after selling 2,588 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned approximately 0.29% of Illumina worth $93,445,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Illumina by 1.4% in the 3rd quarter. Vanguard Group Inc. now owns 12,836,349 shares of the life sciences company’s stock valued at $2,449,047,000 after buying an additional 181,628 shares during the last quarter. Polen Capital Management LLC grew its position in Illumina by 62.0% in the 3rd quarter. Polen Capital Management LLC now owns 4,521,397 shares of the life sciences company’s stock valued at $862,637,000 after purchasing an additional 1,731,169 shares during the period. Veritas Asset Management LLP boosted its holdings in Illumina by 1.8% during the 3rd quarter. Veritas Asset Management LLP now owns 1,591,247 shares of the life sciences company’s stock worth $303,594,000 after acquiring an additional 27,792 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in Illumina by 74.4% during the 3rd quarter. Alliancebernstein L.P. now owns 1,574,461 shares of the life sciences company’s stock worth $300,391,000 after acquiring an additional 671,462 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in Illumina by 4.3% during the 2nd quarter. Legal & General Group Plc now owns 1,297,650 shares of the life sciences company’s stock worth $239,235,000 after acquiring an additional 53,053 shares during the last quarter. 87.97% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of equities analysts have issued reports on the stock. Barclays cut their price objective on shares of Illumina from $160.00 to $150.00 and set an “underweight” rating on the stock in a report on Wednesday, February 8th. UBS Group cut their price objective on shares of Illumina from $255.00 to $240.00 and set a “neutral” rating on the stock in a report on Tuesday, February 14th. Piper Sandler reiterated an “overweight” rating and set a $290.00 target price on shares of Illumina in a research note on Wednesday, February 8th. Canaccord Genuity Group lowered their price objective on Illumina from $330.00 to $300.00 and set a “buy” rating on the stock in a research note on Tuesday, January 17th. Finally, Cowen decreased their price target on Illumina from $350.00 to $296.00 in a research report on Tuesday, January 10th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $249.40.
Illumina Trading Up 2.6 %
Illumina (NASDAQ:ILMN – Get Rating) last announced its earnings results on Tuesday, February 7th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.11). Illumina had a positive return on equity of 3.79% and a negative net margin of 96.12%. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the previous year, the business posted $0.75 earnings per share. The company’s revenue for the quarter was down 9.2% on a year-over-year basis. As a group, equities analysts forecast that Illumina, Inc. will post 1.41 EPS for the current fiscal year.
Insider Transactions at Illumina
In other news, SVP Alexander Aravanis sold 5,398 shares of the firm’s stock in a transaction dated Wednesday, February 22nd. The stock was sold at an average price of $201.74, for a total value of $1,088,992.52. Following the transaction, the senior vice president now owns 2,922 shares of the company’s stock, valued at $589,484.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Illumina news, SVP Alexander Aravanis sold 5,398 shares of the firm’s stock in a transaction that occurred on Wednesday, February 22nd. The stock was sold at an average price of $201.74, for a total transaction of $1,088,992.52. Following the completion of the transaction, the senior vice president now owns 2,922 shares in the company, valued at approximately $589,484.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Susan H. Tousi sold 500 shares of the firm’s stock in a transaction that occurred on Monday, February 6th. The shares were sold at an average price of $211.57, for a total value of $105,785.00. Following the transaction, the senior vice president now owns 38,276 shares of the company’s stock, valued at approximately $8,098,053.32. The disclosure for this sale can be found here. Insiders have sold 9,815 shares of company stock valued at $1,974,496 over the last quarter. 0.13% of the stock is currently owned by company insiders.
Illumina Company Profile
Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions.
Recommended Stories
- Get a free copy of the StockNews.com research report on Illumina (ILMN)
- Delta Airlines Is Ready To Fly Higher
- Global Payments Climbs After Goldman Sachs Upgrade
- Fastenal Is At A Critical Turning Point
- 3 Healthcare Stocks Insiders Are Buying
- Novo Nordisk Charges Higher and Could be Just Getting Started
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Get Rating).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
